La néphropathie lupique : les nouvelles perspectives de traitement

[en] Systemic lupus erythematosus is a chronic autoimmune disease. Both acquired and innate immune systems are involved in the development of this systemic disease. Lupus nephritis usually is the most serious manifestation of systemic lupus erythematosus, with significant morbidity and mortality. The physiopathological development of the renal involvement of lupus has been increasingly elucidated over the years and various target therapies have recently been developed. After some physiopathological reminders, we discuss the conventional treatment of lupus nephritis as well as the various therapeutic advances, in particular the contribution and the place of the new target therapies in the treatment of the lupus nephritis.

Disciplines :

Urology & nephrology
Rheumatology

Author, co-author :

JADOT, Virginie ; Centre Hospitalier Universitaire de Liège - CHU > Service de gastroentérologie, hépatologie, onco. digestive

Krzesinski, Jean-Marie ; Université de Liège - ULiège > Département des sciences cliniques > Néphrologie

VON FRENCKELL, Christian ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de rhumatologie

BOVY, Christophe ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de néphrologie

BOUQUEGNEAU, Antoine ; Centre Hospitalier Universitaire de Liège - CHU > Service de néphrologie

Language :

French

Title :

La néphropathie lupique : les nouvelles perspectives de traitement

Alternative titles :

[en] Lupus nephropathy: Insight in new treatments

Publication date :

2017

Journal title :

Néphrologie et Thérapeutique

ISSN :

1769-7255

eISSN :

1872-9177

Publisher :

Elsevier Masson, Netherlands

Volume :

Pages :

1-12

Peer reviewed :

Peer Reviewed verified by ORBi

Commentary :

Available on ORBi :

since 27 November 2018

Statistics

Number of views

300 (4 by ULiège)

Number of downloads

1011 (8 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Imran, T.F., Yick, F., Verma, S., Estiverne, C., Ogbonnaya-Odor, C., Thiruvarudsothy, S., et al. Lupus nephritis: an update. Clin Exp Nephrol 20 (2016), 1–13.
Rahman, A., Isenberg, D.A., Systemic lupus erythematosus. N Engl J Med 358 (2008), 929–939.
Haute Autorité de santé (HAS). Protocole national de diagnostic et de soins (PNDS). ALD no 21. Lupus érythémateux systémique. www.has-sante.fr/portail/jcms/c_931697/fr/ald-n-21-lupus-erythemateux-systemique.
Seligman, V.A., Lum, R.F., Olson, J.L., Li, H., Criswell, L.A., Demographic differences in the development of lupus nephritis: a retrospective analysis. Am J Med 112 (2002), 726–729.
Somers, E.C., Marder, W., Cagnoli, P., Lewis, E.E., DeGuire, P., Gordon, C., et al. Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program. Arthritis Rheumatol 66 (2014), 369–378.
Bernatsky, S., Boivin, J.F., Joseph, L., Manzi, S., Ginzler, E., Gladman, D.D., et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 54 (2006), 2550–2557.
Ippolito, A., Petri, M., An update on mortality in systemic lupus erythematosus. Clin Exp Rheumatol 26:5 Suppl. 51 (2008), S72–S79.
Mohan, C., Putterman, C., Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nat Rev Nephrol 11 (2015), 329–341.
Lech, M., Anders, H.J., The pathogenesis of lupus nephritis. J Am Soc Nephrol 24 (2013), 1357–1366.
Rönnblom, L., Alm, G.V., Eloranta, M.L., The type I interferon system in the development of lupus. Semin Immunol 23 (2011), 113–121.
Gigante, A., Gasperini, M.L., Afeltra, A., Barbano, B., Margiotta, D., Cianci, R., et al. Cytokines expression in SLE nephritis. Eur Rev Med Pharmacol Sci 15 (2011), 15–24.
Mackay, M., Oswald, M., Sanchez-Guerrero, J., Lichauco, J., Aranow, C., Kotkin, S., et al. Molecular signatures in systemic lupus erythematosus: distinction between disease flare and infection. Lupus Sci Med, 3, 2016, e000159.
Parikh, S.V., Malvar, A., Song, H., Alberton, V., Lococo, B., Vance, J., et al. Molecular imaging of the kidney in lupus nephritis to characterize response to treatment. J Lab Clin Med 182 (2017), 1–13.
Leffler, J., Martin, M., Gullstrand, B., Tydén, H., Lood, C., Truedsson, L., et al. Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J Immunol 188 (2012), 3522–3531.
Lande, R., Ganguly, D., Facchinetti, V., Frasca, L., Conrad, C., Gregorio, J., et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med, 3, 2011, 73ra19.
Dolff, S., Bijl, M., Huitema, M.G., Limburg, P.C., Kallenberg, C.G.M., Abdulahad, W.H., Disturbed Th1, Th2, Th17 and T(reg) balance in patients with systemic lupus erythematosus. Clin Immunol Orlando Fla 141 (2011), 197–204.
Tao, J.H., Cheng, M., Tang, J.P., Liu, Q., Pan, F., Li, X.P., Foxp3, regulatory T cell and autoimmune diseases. Inflammation 40 (2017), 328–339.
Mellor-Pita, S., Citores, M.J., Castejon, R., Tutor-Ureta, P., Yebra-Bango, M., Andreu, J.L., et al. Decrease of regulatory T cells in patients with systemic lupus erythematosus. Ann Rheum Dis 65 (2006), 553–554.
Venigalla, R.K.C., Tretter, T., Krienke, S., Max, R., Eckstein, V., Blank, N., et al. Reduced CD4+, CD25-T cell sensitivity to the suppressive function of CD4+, CD25 high CD127 -/low regulatory T cells in patients with active systemic lupus erythematosus. Arthritis Rheum 58 (2008), 2120–2130.
Krebs, C.F., Turner, J.E., Paust, H.J., Kapffer, S., Koyro, T., Krohn, S., et al. Plasticity of Th17 cells in autoimmune kidney diseases. J Immunol 197 (2016), 449–457.
Elgueta, R., Benson, M.J., de Vries, V.C., Wasiuk, A., Guo, Y., Noelle, R.J., Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 229 (2009), 152–172.
Michaelson, J.S., Wisniacki, N., Burkly, L.C., Putterman, C., Role of TWEAK in lupus nephritis: a bench-to-bedside review. J Autoimmun 39 (2012), 130–142.
Ryffel, B., Car, B.D., Gunn, H., Roman, D., Hiestand, P., Mihatsch, M.J., Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice. Am J Pathol 144 (1994), 927–937.
Deng, Y., Tsao, B.P., Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat Rev Rheumatol 6 (2010), 683–692.
Guo, Y., Orme, J., Mohan, C., A genopedia of lupus genes – lessons from gene knockouts. Curr Rheumatol Rev 9 (2013), 90–99.
Vaughn, S.E., Kottyan, L.C., Munroe, M.E., Harley, J.B., Genetic susceptibility to lupus: the biological basis of genetic risk found in B cell signaling pathways. J Leukoc Biol 92 (2012), 577–591.
Dang, J., Shan, S., Li, J., Zhao, H., Xin, Q., Liu, Y., et al. Gene-gene interactions of IRF5, STAT4, IKZF1 and ETS1 in systemic lupus erythematosus. Tissue Antigens 83 (2014), 401–408.
Verstrepen, L., Carpentier, I., Verhelst, K., Beyaert, R., ABINs: A20 binding inhibitors of NF-kappa B and apoptosis signaling. Biochem Pharmacol 78 (2009), 105–114.
Obermoser, G., Pascual, V., The interferon-alpha signature of systemic lupus erythematosus. Lupus 19 (2010), 1012–1019.
Shao, W.H., Cohen, P.L., Disturbances of apoptotic cell clearance in systemic lupus erythematosus. Arthritis Res Ther, 13, 2011, 202.
Chung, S.A., Brown, E.E., Williams, A.H., Ramos, P.S., Berthier, C.C., Bhangale, T., et al. Lupus nephritis susceptibility loci in women with systemic lupus erythematosus. J Am Soc Nephrol 25 (2014), 2859–2870.
Weening, J.J., D'Agati, V.D., Schwartz, M.M., Seshan, S.V., Alpers, C.E., Appel, G.B., et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65 (2004), 521–530.
Appel, G.B., Contreras, G., Dooley, M.A., Ginzler, E.M., Isenberg, D., Jayne, D., et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20 (2009), 1103–1112.
Rathi, M., Goyal, A., Jaryal, A., Sharma, A., Gupta, P.K., Ramachandran, R., et al. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis. Kidney Int 89 (2016), 235–242.
Anders, H.J., Weidenbusch, M., Rovin, B., Unmet medical needs in lupus nephritis: solutions through evidence-based, personalized medicine. Clin Kidney J 8 (2015), 492–502.
Houssiau, F.A., Lauwerys, B.R., Current management of lupus nephritis. Best Pract Res Clin Rheumatol 27 (2013), 319–328.
Mehat, P., Atiquzzaman, M., Esdaile, J.M., Avina-Zubieta, A., DeVera, M.A., Medication nonadherence in systemic lupus erythematosus: a systematic review. Arthritis Care Res, 2017, 10.1002/acr.23191.
Bertsias, G.K., Tektonidou, M., Amoura, Z., Aringer, M., Bajema, I., Berden, J.H.M., et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 71 (2012), 1771–1782.
Houssiau, F.A., Vasconcelos, C., D'Cruz, D., Sebastiani, G.D., Garrido Ed Ede, R., Danieli, M.G., et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46 (2002), 2121–2131.
Isenberg, D., Appel, G.B., Contreras, G., Dooley, M.A., Ginzler, E.M., Jayne, D., et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatol Oxf Engl 49 (2010), 128–140.
Chan, T.M., Treatment of severe lupus nephritis: the new horizon. Nat Rev Nephrol 11 (2015), 46–61.
Radhakrishnan, J., Cattran, D.C., The, KDIGO., practice guideline on glomerulonephritis: reading between the guidelines-application to the individual patient. Kidney Int 82 (2012), 840–856.
Houssiau, F.A., D'Cruz, D., Sangle, S., Remy, P., Vasconcelos, C., Petrovic, R., et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 69 (2010), 2083–2089.
Dooley, M.A., Jayne, D., Ginzler, E.M., Isenberg, D., Olsen, N.J., Wofsy, D., et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 365 (2011), 1886–1895.
Liu, Z., Zhang, H., Liu, Z., Xing, C., Fu, P., Ni, Z., et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med 162 (2015), 18–26.
Leone, A., Sciascia, S., Kamal, A., Khamashta, M., Biologicals for the treatment of systemic lupus erythematosus: current status and emerging therapies. Expert Rev Clin Immunol 11 (2015), 109–116.
Mok, C.C., Current role of rituximab in systemic lupus erythematosus. Int J Rheum Dis 18 (2015), 154–163.
Merrill, J.T., Neuwelt, C.M., Wallace, D.J., Shanahan, J.C., Latinis, K.M., Oates, J.C., et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62 (2010), 222–233.
Rovin, B.H., Furie, R., Latinis, K., Looney, R.J., Fervenza, F.C., Sanchez-Guerrero, J., et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64 (2012), 1215–1226.
Ramos-Casals, M., Soto, M.J., Cuadrado, M.J., Khamashta, M.A., Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 18 (2009), 767–776.
Fattah, Z., Isenberg, D.A., Recent developments in the treatment of patients with systemic lupus erythematosus: focusing on biologic therapies. Expert Opin Biol Ther 14 (2014), 311–326.
Condon, M.B., Ashby, D., Pepper, R.J., Cook, H.T., Levy, J.B., Griffith, M., et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 72 (2013), 1280–1286.
Mysler, E.F., Spindler, A.J., Guzman, R., Bijl, M., Jayne, D., Furie, R.A., et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum 65 (2013), 2368–2379.
Navarra, S.V., Guzmán, R.M., Gallacher, A.E., Hall, S., Levy, R.A., Jimenez, R.E., et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet Lond Engl 377 (2011), 721–731.
Furie, R., Petri, M., Zamani, O., Cervera, R., Wallace, D.J., Tegzová D., et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63 (2011), 3918–3930.
Ginzler, E.M., Wax, S., Rajeswaran, A., Copt, S., Hillson, J., Ramos, E., et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther, 14, 2012, R33.
Stohl, W., Merrill, J.T., Looney, R.J., Buyon, J., Wallace, D.J., Weisman, M.H., et al. Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Res Ther, 17, 2015, 215.
Alexander, T., Sarfert, R., Klotsche, J., Kühl, A.A., Rubbert-Roth, A., Lorenz, H.M., et al. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis 74 (2015), 1474–1478.
Furie, R., Nicholls, K., Cheng, T.T., Houssiau, F., Burgos-Vargas, R., Chen, S.L., et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol 66 (2014), 379–389.
Wofsy, D., Hillson, J.L., Diamond, B., Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum 64 (2012), 3660–3665.
Trial ACCESS Group, Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study. Arthritis Rheumatol 66 (2014), 3096–3104.
Boumpas, D.T., Furie, R., Manzi, S., Illei, G.G., Wallace, D.J., Balow, J.E., et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 48 (2003), 719–727.
Rovin, B.H., van Vollenhoven, R.F., Aranow, C., Wagner, C., Gordon, R., Zhuang, Y., et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis. Arthritis Rheumatol 68 (2016), 2174–2183.
Illei, G.G., Shirota, Y., Yarboro, C.H., Daruwalla, J., Tackey, E., Takada, K., et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 62 (2010), 542–552.
Ble, A., Mosca, M., Di Loreto, G., Guglielmotti, A., Biondi, G., Bombardieri, S., et al. Antiproteinuric effect of chemokine C-C motif ligand 2 inhibition in subjects with acute proliferative lupus nephritis. Am J Nephrol 34 (2011), 367–372.
Rovin, B.H., Parikh, S.V., Lupus nephritis: the evolving role of novel therapeutics. Am J Kidney Dis 63 (2014), 677–690.
Jayne, D., Appel, G., Chan, T.M., A randomized controlled study of Laquinimod in active lupus nephritis patients in combination with standard of care. Ann Rheum Dis, 72(Suppl. 3), 2013, 164.
Peng, L., Oganesyan, V., Wu, H., Dall'Acqua, W.F., Damschroder, M.M., Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibody. mAbs 7 (2015), 428–439.
He, J., Zhang, X., Wei, Y., Sun, X., Chen, Y., Deng, J., et al. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. Nat Med 22 (2016), 991–993.